c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis
- PMID: 33168981
- PMCID: PMC7116435
- DOI: 10.1038/s42255-020-00306-2
c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis
Erratum in
-
Author Correction: c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis.Nat Metab. 2021 Jan;3(1):118-119. doi: 10.1038/s42255-020-00326-y. Nat Metab. 2021. PMID: 33303984 No abstract available.
Abstract
Fibrosis is a common pathological feature of chronic disease. Deletion of the NF-κB subunit c-Rel limits fibrosis in multiple organs, although the mechanistic nature of this protection is unresolved. Using cell-specific gene-targeting manipulations in mice undergoing liver damage, we elucidate a critical role for c-Rel in controlling metabolic changes required for inflammatory and fibrogenic activities of hepatocytes and macrophages and identify Pfkfb3 as the key downstream metabolic mediator of this response. Independent deletions of Rel in hepatocytes or macrophages suppressed liver fibrosis induced by carbon tetrachloride, while combined deletion had an additive anti-fibrogenic effect. In transforming growth factor-β1-induced hepatocytes, c-Rel regulates expression of a pro-fibrogenic secretome comprising inflammatory molecules and connective tissue growth factor, the latter promoting collagen secretion from HMs. Macrophages lacking c-Rel fail to polarize to M1 or M2 states, explaining reduced fibrosis in RelΔLysM mice. Pharmacological inhibition of c-Rel attenuated multi-organ fibrosis in both murine and human fibrosis. In conclusion, activation of c-Rel/Pfkfb3 in damaged tissue instigates a paracrine signalling network among epithelial, myeloid and mesenchymal cells to stimulate fibrogenesis. Targeting the c-Rel-Pfkfb3 axis has potential for therapeutic applications in fibrotic disease.
Conflict of interest statement
Figures


















Similar articles
-
The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche.J Pathol. 2024 Aug;263(4-5):482-495. doi: 10.1002/path.6299. Epub 2024 Jun 14. J Pathol. 2024. PMID: 38872438
-
The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation.Hepatology. 2010 Mar;51(3):922-31. doi: 10.1002/hep.23385. Hepatology. 2010. PMID: 20058312
-
CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis.Gastroenterology. 2020 Jul;159(1):273-288. doi: 10.1053/j.gastro.2020.03.008. Epub 2020 Mar 10. Gastroenterology. 2020. PMID: 32169429
-
MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway.J Pathol. 2014 Sep;234(1):46-59. doi: 10.1002/path.4373. Epub 2014 Jun 17. J Pathol. 2014. PMID: 24817606
-
The NF-κB subunit c-Rel stimulates cardiac hypertrophy and fibrosis.Am J Pathol. 2012 Mar;180(3):929-939. doi: 10.1016/j.ajpath.2011.11.007. Epub 2011 Dec 30. Am J Pathol. 2012. PMID: 22210479 Free PMC article.
Cited by
-
Deficiency of myeloid NPC1 exacerbates liver injury and fibrosis by impairing macrophage efferocytosis.J Adv Res. 2025 Jun;72:213-227. doi: 10.1016/j.jare.2024.11.020. Epub 2024 Nov 14. J Adv Res. 2025. PMID: 39547438 Free PMC article.
-
Nanotechnology in Drug Delivery for Liver Fibrosis.Front Mol Biosci. 2022 Jan 11;8:804396. doi: 10.3389/fmolb.2021.804396. eCollection 2021. Front Mol Biosci. 2022. PMID: 35087870 Free PMC article. Review.
-
Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ.Nat Cell Biol. 2024 Dec;26(12):2075-2083. doi: 10.1038/s41556-024-01543-3. Epub 2024 Nov 13. Nat Cell Biol. 2024. PMID: 39537753 Free PMC article.
-
Role of CCR2-Positive Macrophages in Pathological Ventricular Remodelling.Biomedicines. 2022 Mar 12;10(3):661. doi: 10.3390/biomedicines10030661. Biomedicines. 2022. PMID: 35327464 Free PMC article. Review.
-
YTHDC2 manipulates anti-tumoral macrophage polarization and predicts favorable outcomes in triple negative breast cancer.NPJ Precis Oncol. 2025 Apr 25;9(1):119. doi: 10.1038/s41698-025-00880-2. NPJ Precis Oncol. 2025. PMID: 40274959 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- MR/R023026/1/MRC_/Medical Research Council/United Kingdom
- A26813/CRUK_/Cancer Research UK/United Kingdom
- MR/K0019494/1/MRC_/Medical Research Council/United Kingdom
- WT107492Z/WT_/Wellcome Trust/United Kingdom
- 26813/CRUK_/Cancer Research UK/United Kingdom
- 20812/VAC_/Versus Arthritis/United Kingdom
- MC_PC_14101/MRC_/Medical Research Council/United Kingdom
- G0401643/MRC_/Medical Research Council/United Kingdom
- L016354/MRC_/Medical Research Council/United Kingdom
- 23390/CRUK_/Cancer Research UK/United Kingdom
- G0700890/MRC_/Medical Research Council/United Kingdom
- 087961/WT_/Wellcome Trust/United Kingdom
- A171196/CRUK_/Cancer Research UK/United Kingdom
- NC/K000748/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction of Animals in Research/United Kingdom
- MR/K001949/1/MRC_/Medical Research Council/United Kingdom
- G0900535/MRC_/Medical Research Council/United Kingdom
- A23390/CRUK_/Cancer Research UK/United Kingdom
- MR/L016354/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases